M&A / Deals Terremoto wins $108m in Series C to drive cancer and rare disease programmes Pharmaceutical TechnologyTerremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.M&A / DealsOncologyRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaceutical Technology Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity. M&A / DealsOncologyRead full story Post navigation Previous: Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy studyNext: Most patients “won’t see benefit” with Alzheimer’s drugs Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026